Literature DB >> 8100194

Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression.

K E Asin1, D Wirtshafter.   

Abstract

Acute injections of the full dopamine D1 receptor agonist A-77636 ((1R,3S)-3-(1'adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1 H-2-benzopyran hydrochloride) induce ipsilateral Fos-like immunoreactivity and contralateral rotation into rats bearing unilateral dopamine depleting lesions. However, following repeated treatment, A-77636 fails to induce either striatal c-fos or rotation. Our results suggest that striatal c-fos activation mirrors behavioral indices of dopamine D1 receptor sensitivity.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8100194     DOI： 10.1016/0014-2999(93)90840-e

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  9 in total

1.  Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Authors:  Jessica P Ryman-Rasmussen; Adam Griffith; Scott Oloff; Nagarajan Vaidehi; Justin T Brown; William A Goddard; Richard B Mailman
Journal:  Neuropharmacology       Date:  2006-10-24       Impact factor: 5.250

2.  Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822.

Authors:  David Wirtshafter
Journal:  Pharmacol Biochem Behav       Date:  2007-01-20       Impact factor: 3.533

3.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

4.  Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists.

Authors:  Benjamin R Chemel; Lisa A Bonner; Val J Watts; David E Nichols
Journal:  Mol Pharmacol       Date:  2012-02-14       Impact factor: 4.436

5.  Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

Authors:  John D McCorvy; Val J Watts; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2012-01-06       Impact factor: 4.530

6.  Tolerance to the procholinergic action of the D1 receptor full agonist dihydrexidine.

Authors:  Mark R Wade; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 7.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

Review 8.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

9.  The Signaling and Pharmacology of the Dopamine D1 Receptor.

Authors:  Jace Jones-Tabah; Hanan Mohammad; Emma G Paulus; Paul B S Clarke; Terence E Hébert
Journal:  Front Cell Neurosci       Date:  2022-01-17       Impact factor: 5.505
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.